HBI Deals+Insights / News
Sanofi, the French global pharmaceutical and healthcare company, has announced it will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases.





